Core Insights - Caris Life Sciences Inc. (NASDAQ:CAI) has expanded its Caris AI Insights portfolio with a new AI signature aimed at predicting early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) [1][5] - The AI tool utilizes the proprietary CodeAI platform to analyze Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to provide insights for clinicians [1][2] Summary by Sections AI Signature and Its Purpose - The new AI signature is designed to give clinicians molecular foresight regarding the duration a patient may benefit from standard platinum-based chemotherapy before disease progression [2] - HGSOC is characterized as an aggressive cancer, with approximately 20% to 30% of patients developing resistance within six months of initial treatment [2] Clinical Application and Technology - The technology generates a risk score and classifies patients as either platinum-sensitive or platinum-resistant, aiding doctors in identifying those who may require a swift transition to alternative therapies [2] - The ovarian cancer AI signature is available through the Caris Molecular Tumor Board Report when utilizing the MI Cancer Seek tissue-based test, which received FDA approval in late 2024 [3][5] Market Context - The introduction of this AI signature is particularly relevant following recent FDA approvals for new combination treatments targeting platinum-resistant cases [3]

Core Insights - OSE Immunotherapeutics is actively participating in investor conferences to engage with wealth managers, financial advisors, and individual investors, showcasing its commitment to transparency and investor relations [1][2]. Company Overview - OSE Immunotherapeutics is a clinical-stage biotech company focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, addressing unmet patient needs [3]. - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [3]. - OSE Immunotherapeutics is headquartered between Nantes and Paris and is listed on Euronext [3]. Upcoming Events - The company will present at the Mardi de la Bourse event in Lyon, France, on April 7, 2026, where the CEO and CFO will engage in a Q&A session [1]. - Additionally, OSE Immunotherapeutics will host investor meetings at the 14th Degroof Petercam Healthcare Conference on May 6, 2026, in a virtual format [2].

Group 1 - Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2 billion [1] - The report cites sources familiar with the matter regarding the acquisition [1]

Core Insights - Senti Biosciences, Inc. is set to present clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference on March 24-25, 2026, in San Diego, California [1] Clinical Data - The ongoing Phase I clinical trial of SENTI-202 focuses on a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy targeting CD33 and/or FLT3, designed to spare EMCN-expressing healthy cells in adults with relapsed/refractory acute myeloid leukemia (AML) [2] - Rochelle Emery, MD, will present promising results from the Phase I clinical trial, highlighting safety and preliminary anti-leukemic activity of SENTI-202 [2] Translational Data - Enping Hong, PhD, will present correlative analyses that support the observed clinical activity of SENTI-202 and its unique logic-gated mechanism of action [3] Workshop Participation - Brian Garrison, PhD, will lead a workshop on strategies to enhance NK cell therapy development through biomarker discovery and translational approaches [4] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies for incurable diseases using its proprietary Gene Circuit platform [5] - The company aims to engineer Gene Circuits that can precisely target and kill cancer cells while sparing healthy cells, with applications in both liquid and solid tumors [5] - Senti Bio has demonstrated the potential of its Gene Circuits in NK and T cells and is exploring their use in other modalities and diseases beyond oncology [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain best practices in content production and search engine optimization [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Viewpoint - Onconetix, Inc. has announced a 1-for-5 reverse stock split of its outstanding shares, effective March 25, 2026, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 5 shares of common stock into 1 share, reducing the number of outstanding shares from approximately 3.6 million to about 0.7 million [3][4]. - The reverse stock split will not affect the number of authorized shares or the ownership percentage of stockholders, except for fractional shares, which will be compensated in cash [3][4]. - The common stock will continue to trade under the symbol "ONCO" on The Nasdaq Capital Market with a new CUSIP number [2]. Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on men's health and oncology, owning Proclarix®, an in vitro diagnostic test for prostate cancer [5]. - Proclarix® has been approved for sale in the European Union and is anticipated to be marketed in the U.S. as a lab-developed test through a license agreement with Labcorp [5].

Core Insights - NKGen Biotech's troculeucel shows promising cognitive benefits in moderate Alzheimer's patients, with 100% of patients stable or improved and 50% improving from moderate to mild cognitive function [1][4][7] Clinical Data - Pooled analyses from two Phase 1 trials indicate that 92% of patients exhibited stable or improved cognitive function, with dose-responsive trends observed [3][5] - At the three-month assessment, all patients demonstrated stability or improvement across multiple cognitive measures, with higher doses (1 to 6 billion cells) correlating with greater benefits [5][6] - Early signs of durability were noted in patients followed for up to 12 months, with improvements maintained throughout treatment [8] Safety Profile - Troculeucel was well-tolerated, with no treatment-related adverse events reported in the Phase 1 studies [9] Biomarker Correlations - Exploratory plasma GFAP analyses showed strong correlations with clinical measures of disease severity, reinforcing its potential as a non-invasive biomarker for Alzheimer's [10][14] - Baseline plasma GFAP levels correlated significantly with cognitive status, and these correlations remained robust following treatment [14]

Core Viewpoint - Humacyte, Inc. is set to release its financial results for the quarter and year ended December 31, 2025, on March 27, 2026, and will provide a corporate and financial update during a conference call [1][2]. Company Overview - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1][3]. - The company manufactures acellular tissues aimed at treating various diseases, injuries, and chronic conditions [3]. - Humacyte's Biologics License Application for its acellular tissue engineered vessel (ATEV), named Symvess, was approved by the FDA in December 2024 for vascular trauma [3]. - The ATEV is currently undergoing late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3]. - The company is preparing for human clinical studies in coronary artery bypass graft surgery and is also in preclinical development for conditions such as type 1 diabetes and pediatric heart disease [3]. - Humacyte's 6mm ATEV for AV access in hemodialysis was the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received Fast Track designation [3]. Upcoming Events - The financial results and corporate update will be presented during a conference call scheduled for March 27, 2026, at 8:00 a.m. Eastern Time [2]. - Investors can join the call using specific contact numbers provided for U.S. and international participants [2].

Core Insights - Damora Therapeutics has appointed Jennifer Jarrett as President and CEO, effective March 30, 2026, bringing nearly three decades of experience in biotech, tech, and finance [1][2] - The company aims to redefine care for patients with blood disorders, particularly focusing on mutant calreticulin-driven myeloproliferative neoplasms (MPNs) [2][7] - The Board of Directors has also appointed Cameron Turtle and Mike Landsittel, enhancing the board's expertise in biotech and capital markets [3][4] Company Leadership - Jennifer Jarrett has a strong background in corporate strategy, finance, and drug development, previously serving as COO of Arcus Biosciences and CFO of Medivation [2][5] - Peter Harwin has been named Chairman of the Board, emphasizing the strategic direction of the company [3][4] - Cameron Turtle and Mike Landsittel bring extensive experience in building and leading biotech companies, with Turtle focusing on development and commercialization and Landsittel on strategic finance [5][6] Strategic Focus - Damora is advancing a portfolio of potential best-in-class therapies aimed at treating MPNs, with plans to enter clinical development in 2026 [7] - The company is positioned to rapidly develop its lead program, DMR-001, while also advancing additional pipeline assets [2][7] - The board acknowledges the contributions of departing directors, highlighting the strategic importance of recent transactions [5]